🎯 check Berzosertib (VE-822) product page
Berzosertib (VE-822) is a highly potent and selective first-in-class ATR inhibitor. It affects ATR-Chk1 and DNA damage response signaling by suppressing Chk1 phosphorylation and disrupting cell cycle checkpoints, effectively inhibiting cancer cell proliferation and promoting apoptosis.